Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
Rang în acțiuni #39175
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Preț acțiune
$0.378
Ultima sincronizare: 2024-05-24
Capitalizare de piață
$618.41K
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează NeuBase Therapeutics, Inc. (NBSE)

Categorie

Raport P/B pentru NeuBase Therapeutics, Inc. (NBSE)
Raport P/B la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor NeuBase Therapeutics, Inc., raportul P/B actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/B de 0.
Istoricul raportului P/B pentru NeuBase Therapeutics, Inc. din 2026 până în 2026
Raport P/B la sfârșitul fiecărui an
An Raport P/B Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raport P/B pentru companii similare sau competitoare
Companie Raport P/B Diferență raport P/B Țara
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE